KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $91.3 million.

  • Ionis Pharmaceuticals' Cash from Investing Activities rose 12680.14% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.9 million, marking a year-over-year increase of 19169.65%. This contributed to the annual value of -$134.0 million for FY2024, which is 3740.77% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Cash from Investing Activities stood at $91.3 million for Q3 2025, which was up 12680.14% from -$120.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Cash from Investing Activities high stood at $212.1 million for Q4 2022, and its period low was -$340.8 million during Q3 2024.
  • In the last 5 years, Ionis Pharmaceuticals' Cash from Investing Activities had a median value of $68.2 million in 2024 and averaged -$14.4 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 220396.49% in 2023, then tumbled by 59598.32% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $95.1 million in 2021, then skyrocketed by 123.06% to $212.1 million in 2022, then tumbled by 112.59% to -$26.7 million in 2023, then surged by 355.36% to $68.2 million in 2024, then skyrocketed by 33.9% to $91.3 million in 2025.
  • Its Cash from Investing Activities stands at $91.3 million for Q3 2025, versus -$120.1 million for Q2 2025 and $170.5 million for Q1 2025.